Clearline Capital LP bought a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 484,022 shares of the company's stock, valued at approximately $7,439,000.
A number of other large investors have also modified their holdings of the stock. Golden State Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at about $39,000. New Age Alpha Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at about $43,000. Compagnie Lombard Odier SCmA acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at about $54,000. Banque Cantonale Vaudoise acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at about $74,000. Finally, Brooklyn Investment Group grew its stake in shares of Teva Pharmaceutical Industries by 403.4% during the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company's stock valued at $77,000 after acquiring an additional 4,014 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.
Teva Pharmaceutical Industries Stock Up 2.5%
NYSE:TEVA opened at $18.94 on Monday. The company has a market capitalization of $21.72 billion, a price-to-earnings ratio of -118.35, a price-to-earnings-growth ratio of 1.12 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80. The stock has a 50-day simple moving average of $17.04 and a 200 day simple moving average of $16.39. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The business had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company's revenue for the quarter was up .3% compared to the same quarter last year. During the same period last year, the firm earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.
Insider Transactions at Teva Pharmaceutical Industries
In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the firm's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the transaction, the insider owned 6,774 shares of the company's stock, valued at $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Eric A. Hughes sold 52,742 shares of the firm's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Company insiders own 0.55% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on TEVA shares. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Truist Financial started coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. UBS Group lowered their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Finally, The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $24.71.
Check Out Our Latest Stock Analysis on Teva Pharmaceutical Industries
About Teva Pharmaceutical Industries
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Featured Stories
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
